Sprint Bioscience AB (publ) (STO: SPRINT)

Market Cap	86.58M
Revenue (ttm)	86.21M
Net Income (ttm)	14.72M
Shares Out	69.82M
EPS (ttm)	0.21
PE Ratio	5.88
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,238
Open	1.246
Previous Close	1.240
Day's Range	1.238 - 1.246
52-Week Range	0.756 - 2.660
Beta	0.50
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 25, 2024

About Sprint Bioscience AB

Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. It develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; and PETRA01, a drug candidate for the treatment of cancer. The company also focuses on research of products for the treatment of tumor metabolism, nash, and diabetes. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 28
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: SPRINT

Financial Performance

In 2023, Sprint Bioscience AB's revenue was 51.69 million, an increase of 62171.08% compared to the previous year's 83,000. Losses were -438,000, -99.27% less than in 2022.